Understanding how ARID1A mutations affect ovarian cancer metabolism
Official title: Characterize the metabolic landscape of ARID1A-mutated ovarian cancer
Funded at University of Minnesota · NIH-11031554 · Data updated 2026-11-12
This study is looking at how certain changes in ovarian clear cell carcinoma cells, specifically those with a mutation in the ARID1A gene, affect their energy production, with the goal of finding new treatment options that could help patients with this type of cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $212,013 |
| NIH project number | 1R21CA287351-01A1 |
| Project ID | NIH-11031554 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with ovarian clear cell carcinoma who have ARID1A mutations.
✕Less likely to help
Patients with ovarian cancer who do not have ARID1A mutations may not benefit from the findings of this research.
What this research studies
This research investigates the metabolic characteristics of ovarian clear cell carcinoma (OCCC) that have mutations in the ARID1A gene. By focusing on the mitochondrial respiration processes in these cancer cells, the study aims to identify specific components of the mitochondrial Electron Transport Chain (mETC) that are crucial for the survival of ARID1A-deficient tumors. The researchers will conduct genetic screenings and proteomic analyses to uncover potential therapeutic targets that could lead to more effective treatments for patients with this type of cancer. This approach is innovative as it seeks to provide insights into the unique vulnerabilities of ARID1A-mutated tumors, which may differ from other cancer types.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with ARID1A-mutated ovarian cancer, improving treatment outcomes and survival rates.
How similar studies have gone: While targeting mitochondrial respiration in cancer is a growing area of interest, this specific approach focusing on ARID1A mutations is relatively novel and has not been extensively tested.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Bazzaro, Martina — University of Minnesota
- Study coordinator: Bazzaro, Martina
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.